Profile data is unavailable for this security.
About the company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-107.49m
- Incorporated2015
- Employees70.00
- LocationRAPT Therapeutics Inc561 Eccles AveSOUTH SAN FRANCISCO 94080-1906United StatesUSA
- Phone+1 (650) 489-9000
- Fax+1 (302) 531-3150
- Websitehttps://rapt.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curis Inc | 10.26m | -45.48m | 34.04m | 48.00 | -- | -- | -- | 3.32 | -7.81 | -7.81 | 1.76 | -1.45 | 0.1549 | -- | 3.52 | 213,729.20 | -68.68 | -37.25 | -94.06 | -41.12 | 98.68 | 96.05 | -443.35 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Carisma Therapeutics Inc | 20.27m | -63.80m | 35.40m | 107.00 | -- | -- | -- | 1.75 | -1.56 | -1.56 | 0.4927 | -0.2665 | 0.2723 | -- | -- | 189,420.60 | -85.73 | -30.87 | -101.81 | -34.47 | -- | -- | -314.78 | -255.66 | -- | -- | -- | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Elevation Oncology Inc | 0.00 | -41.95m | 35.78m | 29.00 | -- | 0.5159 | -- | -- | -0.807 | -0.807 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -40.67 | -- | -43.53 | -- | -- | -- | -- | -- | -- | -375.06 | 0.309 | -- | -- | -- | 51.93 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.52m | 36.13m | 82.00 | -- | 0.4774 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 36.58m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -107.49m | 36.65m | 70.00 | -- | 0.3837 | -- | -- | -2.78 | -2.78 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -69.76 | -46.30 | -77.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| AN2 Therapeutics Inc | 0.00 | -60.70m | 36.75m | 41.00 | -- | 0.419 | -- | -- | -2.04 | -2.04 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -48.27 | -- | -53.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -16.26m | 37.18m | 5.00 | -- | 13.47 | -- | -- | -1.18 | -1.18 | 0.00 | 0.2005 | 0.00 | -- | -- | 0.00 | -147.61 | -- | -171.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| OS Therapies Inc | 0.00 | -7.42m | 37.23m | 4.00 | -- | -- | -- | -- | -0.3566 | -0.3566 | 0.00 | -0.0334 | 0.00 | -- | -- | 0.00 | -559.23 | -- | -- | -- | -- | -- | -- | -- | -- | -2.13 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Lumos Pharma Inc | 2.21m | -34.92m | 37.45m | 30.00 | -- | 7.62 | -- | 16.98 | -4.29 | -4.29 | 0.2705 | 0.5682 | 0.0676 | -- | 12.75 | 66,818.18 | -107.08 | -29.78 | -132.78 | -32.32 | -- | -- | -1,583.49 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -27.95m | 37.66m | 41.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -1.10 | 0.00 | -- | -- | 0.00 | -208.29 | -- | -2,279.15 | -- | -- | -- | -- | -- | -- | -28.13 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| FibroGen Inc | 180.01m | -121.79m | 38.88m | 486.00 | -- | -- | -- | 0.216 | -1.23 | -1.23 | 1.81 | -2.42 | 0.4967 | 1.29 | 7.49 | 370,399.20 | -34.51 | -30.62 | -103.81 | -42.31 | 76.87 | 93.52 | -69.48 | -119.08 | 1.16 | -7.70 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.92m | 38.90m | 2.00 | -- | 20.49 | -- | -- | -0.306 | -0.306 | 0.00 | 0.0732 | 0.00 | -- | -- | 0.00 | -137.58 | -- | -154.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 38.91m | 37.00 | -- | 0.9077 | -- | 5.26 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 5.24m | 15.00% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.13m | 8.97% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.25m | 6.46% |
| Kingdon Capital Management LLCas of 30 Sep 2024 | 1.73m | 4.94% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 1.05m | 3.00% |
| Millennium Management LLCas of 30 Sep 2024 | 959.97k | 2.75% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 842.16k | 2.41% |
| Federated MDTA LLCas of 30 Sep 2024 | 798.60k | 2.29% |
| Two Sigma Advisers LPas of 30 Sep 2024 | 705.00k | 2.02% |
| Geode Capital Management LLCas of 30 Sep 2024 | 683.18k | 1.96% |
